United States, Nevada, Las Vegas, DelveInsight’s ‘Developmental and Epileptic Encephalopathy Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Developmental and Epileptic Encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Developmental and Epileptic Encephalopathy pipeline domain.
Key Takeaways from the Developmental and Epileptic Encephalopathy Pipeline Report
Developmental and Epileptic Encephalopathy Overview
Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox–Gastaut syndrome (LGS), Landau–Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep, Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE.
Developmental and Epileptic Encephalopathy Pipeline Analysis: Drug Profile
Epidiolex (Cannabidol): Jazz Pharmaceuticals
Epidiolex (formerly GWP42003-P), also known as Epidyolex in Europe, is the first prescription, plant-derived cannabis oral formulation developed by GW pharmaceuticals. It is a novel class of antiepileptic medications with a different mechanism of action. It has been approved in the US and Europe for the treatment of seizures associated with LGS or Dravet syndrome in patients 2 years of age and older. The drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD).
Discover more about the emerging Developmental and Epileptic Encephalopathy drugs @ Developmental and Epileptic Encephalopathy Treatment Drugs
Developmental and Epileptic Encephalopathy Key Companies
Developmental and Epileptic Encephalopathy Pipeline Therapies
Developmental and Epileptic Encephalopathy Pipeline Therapeutics Assessment
Scope of the Developmental and Epileptic Encephalopathy Pipeline Report
Find out more about the Developmental and Epileptic Encephalopathy treatment options in development @ Developmental and Epileptic Encephalopathy Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies in the diabetic epileptic encephalopathy pipeline domain.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/